<DOC>
	<DOCNO>NCT00231387</DOCNO>
	<brief_summary>This phase IIIb , randomise , double blind , placebo control , study patient type 2 diabetes mellitus coexist vascular disease hypertension . The total duration study approximately 60 week . The aim study examine potential beneficial effect rosiglitazone carotid atheroma patient type 2 diabetes mellitus coexist vascular disease hypertension . It hypothesise treatment rosiglitazone lead decrease plaque size . In addition , hop rosiglitazone positive effect plaque composition stability .</brief_summary>
	<brief_title>Rosiglitazone And Plaque Study Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Inclusion criterion : Type 2 diabetes . Coexisting vascular disease . At least 6 month statin fibrate therapy . HbA1c &lt; 10 % screen least one atheromatous plaque cause 1095 % narrow internal carotid artery . Exclusion criterion : Patients &gt; 2 concomitant oral antihyperglycaemic agent within 3 month screen . Previous exposure thiazolidinedione . History chronic insulin use . Use investigational drug within 30 day . Systolic blood pressure ( bp ) &gt; 170 mmHg diastolic bp &gt; 100 mmHg . Severe unstable angina . History : gangrene , TIA , stroke , hepatic disease , alcohol drug abuse , surgery carotid artery claustrophobia .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>diabetes rosiglitazone plaque</keyword>
</DOC>